Factors Associated with Bullous Pemphigoid After Immune Checkpoint Inhibitor Therapy: A Real-World Cohort Study
Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a morbid cutaneous immune-related adverse event with limited data on clinical predictors. We conducted a retrospective cohort study using the TriNetX research database of adults with malignancy receiving at least two ICI administrations. Among 96,405 ICI-treated patients, 317 (0.33%) developed BP within 3 years of ICI initiation at a median of 375 days. Increased BP risk was associated with age 65–75 years (HR 2.14, 95% CI 1.6–2.9), age ≥75 years (HR 3.80, 2.8–5.2), male sex (HR 1.81, 1.4–2.4), renal cancer (HR 2.02, 1.4–3.0), bladder cancer (HR 1.94, 1.3–2.9), cutaneous melanoma (HR 1.77, 1.2–2.6), head and neck cancers (HR 1.58, 1.0–2.5), and DPP-4 inhibitor exposure (HR 2.47, 1.3–4.6). These findings identify demographic, tumor-specific, and medication-associated factors associated with ICI-BP that may support earlier recognition and risk stratification.
Authors
- Eli Kasheri (ORCID: https://orcid.org/0000-0002-1209-7511)
- Janellen Smith
- Xiying Fan
Institutions
- University of California, Irvine (US)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1093/ced/llag469
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00